C4 Therapeutics (CCCC) Other Non-Current Assets (2019 - 2026)

C4 Therapeutics' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 50.8% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was $3.9 million, a 50.8% increase from a year earlier, with the FY2025 full-year figure at $3.7 million, up 38.72% from the prior year.
• Other Non-Current Assets climbed to $3.9 million in Q1 2026 per CCCC's latest filing, from $3.7 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $5.2 million in Q1 2024 and bottomed at $1.3 million in Q3 2022.
• The 5-year median for Other Non-Current Assets is $3.4 million (2023), against an average of $3.2 million.
• Across the five-year window, Other Non-Current Assets jumped 502.76% in 2022 and tumbled 50.98% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $3.3 million in 2022, then dropped by 16.96% to $2.7 million in 2023, then retreated by 2.5% to $2.7 million in 2024, then soared by 38.72% to $3.7 million in 2025, then increased by 4.94% to $3.9 million in 2026.
• Per Business Quant, the three latest CCCC Other Non-Current Assets figures stand at $3.9 million (Q1 2026), $3.7 million (Q4 2025), and $3.4 million (Q3 2025).